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Human embryonic stem cells (hESCs) hold great promises in many aspects of 
research and clinical usage. Comparing with other type of stem cells such as adult 
stem cells and induced pluri-potent stem cells (iPSCs), hESCs are unique with 
many advantages such as their pluripotency, capable of unlimited self-renewal 
with intact chromosomal integrity. In daily life, we are subjected to bone injuries 
and illnesses which our bodies are unable to recover by themselves. The 
emergence of tissue engineering and cell therapy in the past decades has shown 
some progress in both research and clinical practice. However, the exploration of 
hESCs in such applications is still far early from practice. This study aims to open 
the horizon for the use of hESCs as a cellular model for implant testing and drug 
discovery along its differentiation process toward osteogenic lineage. Most of the 
current implant testing relies on adult stem cell (Mesenchymal stem cells, etc.) 
and primary cells from human tissue. However, the main disadvantage of using 
such cells is, they produce large variations from batch to batch. hESCs and their 
derivatives are special groups of cells like other cells from our body, and able to 
be passaged for long term testing with minimal variations. Here, we first studied 
the possibility of using hESCs as a model for drug discovery in osteoblast lineage 
generation. Conventional osteoblast lineage differentiation from hESCs depends 
purely on cock-tail supplements (Dexamethason, β -glyceralphosphate and 
ascorbic acid). In our studies, in addition to the cock-tail supplements, we found 
that a small molecule purmorphamine was able to enhance the osteogenic 
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potential of hESCs greatly, which demonstrates that hESCs can be used as a 
model for drug discovery along their differentiation process. Also, we explored the 
use of hESCs and their derivatives as a model for implant testing. Conventional 
testing of medically used implants involves the use of immortalized cell lines. 
Though the testing results are consistent, those cell lines are not able to represent 
human physiology fully because lack of chromosomal integrity. hESCs and their 
derivatives are genetically untouched cells and able to be passaged without limit. 
Use of hESCs and derivatives for implant testing not only helps us to examine 
how normal human cells respond to the implant, but also helps us to understand 
development of osteoblast cells that constitute the bone and their function. In sum, 
either as a model for drug discovery or implant testing, hESCs are able to perform 
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Our bodies are subjected to injury and malfunctions from a variety of sources every 
day. They are constantly repairing themselves to ensure our long-term survival. 
However, certain damages are beyond our bodies repair capability and need 
immediate treatment to protect them from further damages. Some times, medical 
implants shall be transplanted to replace the missing biological structure or support 
proper function of adjacent tissues. Expectations are high for treatment of such 
damage and disorders. However, medical and surgical therapies are always either 
ineffective or impractical. The emergence of tissue engineering has shown certain 
progress regarding this historical condition.   
 
1.1 Tissue engineering: 
 
The term of tissue engineering has been used very frequently since its emergence in 
1988. It is the use of a combination of cells, engineering and materials, with certain 
biochemical factors to mimic biological functions in tissue failure or malfunction. In 
practice, it has a broad range of applications such as repair or replace portions of or 
whole tissues such as bone, cartilage, blood vessels even the heart valve with artificial 
implants[1].   
 
1.1.1 Materials of implants: 
 
Many types of materials are currently used in clinical applications and commercially 
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available, such as ceramics, composite materials, metal alloys, bio-absorbable 
materials, silicone, etc. Most of these materials share similar physical 
properties---strength, resistance to abrasion and corrosions. In our daily activities, we 
place high levels of mechanical stress on our body especially on our bones and joints. 
The implant must be able to withstand these stresses day to day without breaking or 
changing its shape. While strength of the implants is important, it must also be 
resistance to abrasions. Frictions on the implant may create particles that cause 
inflammation of surrounding tissues. In the long run, implant materials are subject to 
corrosion from our body fluids creating particles similar to abrasion. Severe 
weakening of the implants may ultimately cause failure of transplantation or damage 
of surrounding tissue. Despite of these physical properties, biocompatibility testing 
ensures safe transplantation of the implants.  
 
1.1.2 Biocompatibility  
 
Biocompatibility refers to the way materials interact with our body. It is related to the 
behavior of biomaterials in several contexts. Firstly, implant material should not elicit 
any toxicity or injurious effects on biological hosts. Some materials, lead and mercury 
for example, are naturally harmful when taken into the body, so are not suitable for 
implanting. Also, it should not trigger any immunological reactions after 
transplantation. More importantly, it should have the ability to perform its desired 
function with respect to a medical therapy which should be beneficial to the host, 
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such as generating appropriate cellular or tissue response to optimize its performance. 
Majority tests of biocompatibility for implant materials were done in the in vitro 
environment on immortalized cell lines in accordance with ISO10993 (or similar 
standards)[2]. Such tests do not determine the biocompatibility of materials to host, 
but they constitute an important step towards the in vivo animal tests and future 
clinical applications. Up to date, most of biocompatibility tests are performed using 
commercially immortalized cell lines. However, such cell lines are either from animal 
origin or genetically modified human cells. Strictly speaking, majority of the cell 
lines used currently cannot resemble human physiology fully. Hence, exploring a 
stable standard cell line that best reflects human physiology is in need. In this book, 
we explore the possibility of using human embryonic stem cells and derivatives as 
cellular model in implant testing for two main reasons. One, human embryonic stem 
cells are the very original cells that our human body is developed from, it best reflects 
human physiology than any other cells lines. Secondly, stable cell lines can be 
derived from hESCs when giving specific stimuli. Such differentiation process is not 
only meant to obtain stable cell lines that resembles human physiology best, but also 
enables us to explore the specific drugs for human development and diseases.  
 
1.2 Stem cells: 
 
Often, the tissue involved in replacement not only requires the mechanical and 
structural support from implants, but has also the efforts to perform specific 
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biochemical or physiological functions involving in embedding cells in the artificial 
implants. Hence, regenerative medicine is always used synonymously with the term 
tissue engineering, although regenerative medicine emphases more on the use of stem 
cells. In addition to biomaterial implants and factors inducing stem cell differentiation 
towards specific lineages, the emerging field of regenerative medicine requires a 
reliable source of stem cells[3]. Up to date, Stem cells are still of great scientific, 
social and political interest in this new millennium primarily because of their function 
in replenishing specialized somatic cells and maintaining normal turnover of 
regenerative organs such as blood, skin and intestinal tissues. 
 
1.2.1 Significance in the use of stem cells: 
 
Through research into human growth and cell development, stem cells provide 
medical benefits in fields such as therapeutic cloning and regenerative medicine. With 
the great potential for discovering new treatments and cures to disease including 
Parkinson‘s disease, schizophrenia, Alzheimer‘s disease, Cancer, spinal cord injuries, 
diabetes and many more, stem cells may also materialized the hope of growing limbs 
and organs in laboratory for transplantation in future. Currently, stem cells can be 
used in testing millions of potential drugs and medicine without the use of animals or 
human volunteers. Comparing with immortal cell lines and animal models, stem cell 
reflects the best human physiology. When used for drug testing, stem cell or its 
derivatives are able to reveal whether the drug is useful to restore physiological 
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function or elicit any side effect to a specific lineage of cells in our body. Stem cell 
research also benefits the study of development stages that cannot be studied directly 
in human embryo providing mechanisms, preventions and cures for birth defects, 
pregnancy loss and infertility. Through stem cell research, scientists has already 
found out the reason for aging and provided many treatments to help slow the aging 
process[4], with further researches done, more mechanisms will be unveiled and 
aging would possibly be reversed to prolong our lives.  
 
1.2.2 Definition of stem cells: 
 
Stem cells are found in most multi-cellular organisms. They can be isolated or 
derived from the embryo, fetus or adult that has, under certain conditions, posses the 
ability of self renewal for long period of time by mitotic division. They are 
unspecialized cells, but can give rise to specialized cells that make up tissues and 
organs in the body. By conventional categorization, there are mainly two types of 
stem cells, adult stem cells (also named as somatic stem cells), and embryonic stem 
cells[5]. However, a third type of pluripotent cell was introduced in 2007 through 
genetic manipulation of somatic cells. With the successful retroviral transduction of 3 
or 4 transcriptional factors, mouse and human somatic cells can be reprogrammed to 
a pluripotent state similar to embryonic stem cells, which was subsequently named as 
induced pluripotent stem (iPS) cells[6-7].  
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1.2.2.1 Adult stem cells 
 
The term adult stem cell refers uncommitted cell that is found in a differentiated 
(specialized) tissue that has two basic properties: the ability of self-renewal and 
differentiate to yield the major specialized cell types of the tissue or organ it 
originated from[5].  
 
Each tissue and organ in our body is made up of cells with specialized functions and a 
finite life span. For example, a neuron specialized in the conduction of electrical 
impulses; a hepatocyte specialized in detoxifying our bodies; a cardiomyocyte is 
specialized in contractions that generate our heartbeats. In case of specialized cell 
death or under conditions such as tissue damage, stem cells in our body play the key 
role in replenishing such cells.  
 
Study of adult stem cells can trace back in the early 1960, when Joseph Altman and 
Gopal Das discovered neurogenesis in guinea-pig[8], which is the first scientific 
discovery in the creation of adult neurons in adult brain, suggesting ongoing stem cell 
activity in adults. Later in 1963, McCulloch and Till illustrated the presence of 
self-renewing cells in mouse bone marrow through colony formation rising from a 
single cell [9-10]. Still, their work did not draw much attention on the regenerative 
properties of stem cells until in 1968, after a successful transplantation of bone 
marrow between two siblings to treat Severe Combined Immunodeficiency (SCID). 
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Ten years after scientists realized the great potential of stem cells in medical 
treatments and therapy, in 1978, the very first hematopoietic stem cell was discovered 
in cord blood giving rise to possible treatments for certain blood and immune diseases 
such as leukemia and anemia[11].  
 
Over half a century‘s excitement research on adult stem cells, many types of stem 
cells were found in many more tissues than once thought possible. From the very first 
discovery of hematopoietic stem cells in born marrow, mesenchymal stem cells (MSC) 
have been isolated from placenta, adipose tissue, lung, bone marrow and blood[12]. 
Neural stem cells have been isolated and cultured in vitro as neurosphere[13]. 
Olfactory adult stem cells have been isolated from olfactory mucosa [14]. Mammary 
stem cells have been isolated from mammary gland [15-16]. Adipose-derived stem 
ADS) cells from human adipose tissue [17]. Stem cells from dental pulp have been 
found to have same cellular markers and differentiation abilities of mesenchymal 
stem cells [18]. Given the right condition, some of these stem cells can differentiate 
into a number of specialized cell types, for example, MSC and ADS can differentiate 
into osteo-lineage, adipo-lineage and chondro-lineage cells. With optimal control of 
in vitro differentiation, these cells may result in tremendous benefits for many 
patients with serious diseases.  
 
With the exciting hope of adult stem cell therapies, there are still problems holds great 
concerns from scientists, clinicians and patients. Adult stem cells are rare in mature 
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tissues and methods for expanding their numbers in culture have not yet been worked 
out, which are the primary difficulties in using adult stem cells for regenerative 
medicine practically. Cell therapy using adult stem cells should meet the following 
criteria as well. Cells should be easily extracted with minimally invasive procedures 
from host. They should be able to differentiate into multiple lineages in a 
reproducible manner with proper regulations. They should be transplanted into 
autologous or allogeneic host safely and effectively[19].  
 
In earlier this year, donor derived brain tumor after neural stem cell transplantation 
for ataxia telangiectasia was reported [20]. This report reemphasized another 
important problem of stem cells studies, which is the characterization of stem cells 
should be thoroughly studies to avoid Graft-Versus-Tumor effect. It has been reported 
that adipose derived stem cells undergo malignant transformation after more than 4 
month passaging even in in vitro studies [21]. Currently, there is still lack of a 
universal standard for the nomenclature and characterization of adult stem cells. For 
example, adipose derived stem cells share similar surface markers expression profiles 
with bone marrow derived mesenchymal stem cells and able to differentiate into same 
mesoderm lineages[22-23]. This might be an extension of current technical problems 
in obtaining pure, uniform sample of adult stem cells. Such difficulty challenge 
scientists on drawing conclusions on the consistency of their experiments. As 
discussed above, the problems we face today, may severely limit the use of adult stem 
cells either in research or clinical applications.  
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1.2.2.2 Embryonic stem cells: 
 
Another type of stem cells by conventional categorization is embryonic stem cells 
based on its origin from the fertilized egg. In 1981, embryonic stem cells (ESC) were 
first isolated and derived from mouse embryos by Martin Evans and Matthew 
Kaufman from University of Cambridge and Gail R. Martin from University of 
California [24-25]. Briefly, ESCs were derived from inner cell mass of 3 to 5 days 
embryo named as blastocyst. They established culture conditions for growing 
pluripotent mouse ESC in vitro. The ESCs posses normal diploid karyotypes and able 
to generate derivatives of all three germ layers. Injecting the ESCs into mice induced 
the formation of teratomas. 17 yeas after the first derivation of mouse ESCs, a 
breakthrough occurred when Thomson et. al derived the very first line of human 
ESCs from the inner cell mass of normal human blastocysts. The cells are cultured 
through many passages until today and distributed around the globe. The hESCs still 
retain their normal karyotypes and high levels of telomerase activity. When injected 
into immuno-deficient mouse, teratomas were formed including cell types from all 
three germ layers [26].  
 
When given no stimuli for differentiation, ESCs maintain pluripotency through 
multiple cell divisions. Because of their pluripotency and potentially infinite 
competence of self-renewal, ESCs hold great promises in many research areas and 
applications. Study of embryonic stem cells helps us to unveil secrets of human 
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development. hESCs can be used to identify drug targets and test potential 
therapeutics. They can also be used for toxicity testing. Also, studying hESCs help us 
to understand prevention and treatment of birth defects. More importantly, studying 
hESCs differentiation towards somatic lineages proposed enormous therapeutic 
potential for regenerative medicine and tissue replacement after injury or disease.  
 
After the very first isolation and derivation, intensive hESCs researches are 
conducted to look for better ways to harness the potential of stem cells for possible 
medical treatment and therapies. Below are some of the remarkable achievements in 
the past decade: 
 
 Establishing long term viability of human embryonic stem cells in a feeder-free 
system[27].  
 Differentiation of hESCs in 3-D polymer implants for specific shapes [28]. 
 hESCs derivatives facilitate motor recovery of rats to restore movements from 
paralysis[29]. 
 Establishing human feeder layers supporting prolonged expansion of hESC 
culture[30]. 
 Achieved homologous recombination in hESCs[31].  
 hESCs derivative may help to treat vision loss[32]. 
 Large scale culture method to produce blood cells from hESCs[33]. 
 hESCs derivative cure mouse model of hemophilia[34]. 
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 Motor neurons generated from hESCs[35]. 
 Insulin-producing cells genereated from hESCs[36]. 
 Establishing xeno-free condition for hESCs culture[37]. 
 Cardiomyocytes derived from hESCs restored infarcted rat heart function [38]. 
 hESCs give rise to lung alveolar epithelial type II cells[39].  
 Natural killer cells with potent in vivo antitumor activity generated from 
hESCs[40]. 
 
Marking the first hESCs human trial in the world, U.S. Food and Drug 
Administration (FDA) approved Phase I clinical trials for transplantation of human 
ES derived progenitor cells into spinal cord injured patient on Jan 23, 2009. Behind 
this approval, was the study by Hans Keirstead, et.al from University of California. 
Their results showed that injection of human ES cells derived oligodendrocyte 
progenitor cell into spinal cord injured rats has a significant improvement in 
restoration of their locomotion after 7 days of injury [41]. In the summer of 2009, 
FDA approved the first clinical trial for the use of ESCs in human. Biotech team of 
Geron Corporation will be initializing the trial. Patients with only less than two weeks 
spinal cord injury will be recruited in this trial based on animal experiments. This trial 
is focusing on testing the safety of transplantation procedures, but future studies may 
involve in severe disabilities.   
 
As discussed earlier on adult stem cells, it is difficult to isolate and extract them, and 
 13 
their reproductive capacity is more limited comparing with hESCs. Additionally, only 
a few of the 220 types of cells have been produced using adult stem cells. However, 
with the greater potential of differentiation into all 3 primary germ layers, ESCs as 
the mother cell are more capable to be used for regenerative medicine. Finally, one of 
the major ongoing debates on stem cell research is to reduce donor-host rejection. 
There are three solutions for this problem. One is to create pluripotent stem cells that 
are genetically equal to patients by means of therapeutic cloning through somatic cell 
nuclear transfer. However, this is costly and success rate is really low with severe 
genetic defects. Another way is to derive various well-characterized ES cell lines 
from different Human leukocyte antigen (HLA) groups and select the best fit for 
patients. Using this method, it is time consuming for the derivation and subject to 
ethic control when deriving new cell lines using embryo. The third way is through 
genetic manipulation of somatic cells to creat iPSCs.  
 
1.2.2.3 Induced pluripotent stem (iPS) cells: 
 
Induced pluripotent stem cells, normally abbreviated as iPS cells or iPSCs, is the third 
major type of stem cells in the fame of study. They are artificially made pluripotent 
by introducing viral factors or other means to induce forced expression of certain 
genes using somatic cells. The first generation of iPSCs was introduced by Shinya 
Yamanaka‘s team in Japan in 2006. They used genes Oct-3/4, SOX2, c-Myc and Klf4 
which are identified as particularly important in pluripotency. Those four genes were 
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retrovirally transfected to mouse fibroblasts converting them to pluripotent stem cells 
[42]. One year later in 2007, a milestone was achieved by creating iPSCs from human 
adult somatic cells by two independent teams led by Shinya Yamanaka and James 
Thomoson. Yamanaka‘s group used the same retroviral system as they did for mouse 
fibroblasts [7]. While for James Thomson‘s group, Junying Yu, who is the leading 
author, used a lentiviral system with different set of genes, OCT4, SOX2, Nanog and 
LIN28 [6].      
 
Induced pluripotent stem cells are believed to be identical to natural hESCs in many 
aspects. Up to now, stem cell genes and proteins, chromatin methylation patterns, 
doubling time, embryoid body formation, teratoma formation, plasticity and 
differentiation potential are all studied comparing with natural occurring hESCs. In 
addition, a full spectrum of other characteristics of these iPSCs is still under 
evaluation.  
 
This technology has brought promising future aspects to generate patient and disease 
specific pluripotent stem cells in two folds. One, making such cells helps us in 
research to understand disease mechanisms, drug screening and toxicity studies. The 
other use will be producing customized cells for transplantation without immune 
rejection. However, there are concerns of using such cells in clinical applications. For 
example, viruses are used to randomly insert pluripotent genes to alter the cell fate. It 
is very possible that the insertion will result in cancerous cells. To overcome such 
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danger of generating tumor, in 2008, Hochedlinger K and his team found a new 
system in making iPSCs. They used an adenovirus to transport the four genes into 
DNA of murine skin and liver cells without combination of its own genes with the 
targeted cells [43]. Hence, the danger of creating tumors is much more eliminated. 
Later in the same year, Yamanaka‘s group published another paper on generating 
iPSCs using a totally viral free system. The four genes were introduced mouse cells 
by plasmid without evidence of plasmid integration [44]. The drawback of this 
system is its low efficiencies.  
 
In April 2009, another breakthrough in making iPSCs was published by Sheng Ding‘s 
team from the Scripts Institute, California. They reported an alternative way of 
inducing pluripotency without any genetic alteration of the adult somatic cells. They 
repeatedly introduce certain proteins channeled into the cells via poly-arginine 
anchors and sufficiently induced pluripotency[45]. This new technique brings in new 
hope in stem cell research especially in generating stem cells without any viral factors 
involved. It also eases concerns on the safety use of induced pluripotent stem cells in 
clinical applications. However, the research of iPSCs is just getting started. It is still 
too early to draw any conclusions on their potential uses.  
 
After detailed literature review and comparison for all three types of stem cells, adult 
stem cells, embryonic stem cells and induced pluripotent stem cells, embryonic stem 
cells are inevitable and irreplaceable source to be studied. Hence, for the projects 
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reported and discussed the in this book, we only focus on the use of human 
embryonic stem cell as a model in drug discovery towards osteogenic lineage and 
implant testing of potential dental use. The significance of the projects will be 


























2.1 Materials and methods: 
 
2.1.1 Culture of H9 hESCs 
 
The hESCs H9 line was purchased from the Wicell Research Institute Inc. 
(Agreement No. 04-W094, Madison, Wisc., USA). It was listed on the National 
Institute of Health (NIH) stem cell registry, approved by US government-supported 
research funding. Strictly following Wicell protocols, hESC H9 line was cultured and 
propagated in the following conditions. hESC cells were propagated on mitomycine 
C inactivated P4 murine embryonic fibroblast(MEF) cells harvested from CF-1 
inbred mouse strain. The culture medium used for expanding MEF cells are high 
glucose DMEM (Sigma, St. Louis, MO, USA)supplemented with 10% fetal bovine 
serum (FBS, Hyclone, UT, USA). The inactivated MEF feeder cells were seeded in a 
density of 2*10
5
 cells per well in six well plates 24 hours before hESCs seeding. 
Ahead of seeding hESCs on the feeder layer, feeder cells were washed with 
phosphate buffered saline (PBS, FirstBase, Singapore) and cultured on hESCs 
specific medium subsequently. The culture medium used for  culturing hESCs is 
DMEM/F12 (Gibco-BRL Inc., Franklin Lakes,N.J., USA) supplemented with 20% 
Knock out serum replacement (KSR, serum-free formulation; Gibco-BRL Inc.),1mM 
L-glutamine(GIBCO), 1% nonessential amino acid(GIBCO), 100mM 
2-mercaptoethanol (Sigma, St Louis, MO, USA), and 4ng/ml basic Fibroblast growth 
factor (bFGF; Gibco-BRL Inc.). Cells were cultured on 6-well culture plates 
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(Becton-Dickinson Inc., USA) in humidified 5% CO2 incubator at 37
o
C. The culture 
media were changed daily and the cells were passaged when confluence in about 5-7 
days interval. hESCs were dissociated from MEF layers by 1mg/ml of collagenase IV 
treatment for 5mins before manual scrapping to smaller cell aggregate clumps using 
serological pipettes. Clumps of cells were collected and centrifuged at 200g for 5mins 
before seeding for further passages or differentiation.   
 
2.1.2 Embryoid body (EB) formation: 
 
H9 cell colonies were detached from MEF layers by treatment of 2mg/ml of 
collagenase type IV for 30 mins. Floating H9 colonies were collected and splitted into 
small colonies by frequent pipetting. Subsequently, small H9 colonies were 
transferred to low-attachment 6 well plates (Corning Inc. Corning , N. Y. USA) in EB 
culture medium in humidified 5% CO2 incubator at 37
o
C. EB medium includes 
DMEM/F12 (Gibco-BRL Inc, USA) supplemented with 20% Knock out serum 
replacement (KSR, serum-free formulation; Gibco-BRL Inc.), 1mM L-glutamine 
(GIBCO), 1% nonessential amino acid (GIBCO) and 100mM 2-mercaptoethanol 
(Sigma, St Louis, MO, USA). The culture media were changed every 2-3 days. 3 days 
and 5 days EBs were collected by a brief centrifugation for further tests.  
 
2.1.3 Pluripotency of H9 hESCs: 
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To ensure the H9 cells subject to differentiation or implant tests are pluripotent. 
Pluripotency tests are performed ahead of experiment set up. There are basically 3 
criteria for the pluripotency of hESCs. Firstly, when cultured in 2-D, cells should 
have distinct margin from feeder layers. Secondly, cells should have the expression of 
pluripotency markers Oct4, SSEA and Nanog. Lastly, the cells should be able to form 
teratomas when injected into animal models and they should be able to differentiate 
into cells from all primary 3 germ layers namely endoderm, mesoderm and 
ectoderm[5].  
 
2.1.4 Polymerase chain reactions for pluripotent markers: 
 
Undifferentiated hESCs H9 colonies were washed with PBS for three times and 
subsequently detached from mouse feeder layer by treatment of 2mg/ml collagenase 
IV for 30mins. The floating colonies were collected and washed with PBS for three 
times again. Total mRNA was extracted from collected H9 cells, 3 days EB and 5 
days EB colonies using RNeasy Kit (QIAGEN, Chatsworth, CA, USA). cDNA was 
synthesized with 500ng RNA using iScript cDNA synthesis Kit (Bio-Rad，Hercules, 
CA，USA).  
 





Gene Primer sequence 
Annealing 
Temp. 
















2.1.5 Immunocytochemical staining for pluripotent markers: 
 
After washed with PBS for three times, undifferentiated H9 colonies were fixed with 
0.5ml of 4% (v/v) Para-formaldehyde (Sigma) per well for 15 minutes at room 
temperature, followed by permeabilization for 10 minutes with 0.2% Triton X-100 in 
PBS and blocking for one hour with 5% goat serum and 2% BSA (Sigma) in PBS. 
Primary antibody rabbit anti human Oct4 (1:200/PBS, Santa Cruz Biotechnology Inc., 
USA) was incubated with cells at 4ºC overnight and further incubated with Alexa 
Fluor 594 goat anti-rabbit IgG secondary antibody (1:200, Invitrogen, California, 
USA) for detection. Primary antibody mouse anti human Stage-Specific embryonic 
antigen-4 (SSEA-4, 1:400) were incubated with cells without permeabilization and 
were further incubated with Alexa Fluor 488 goat anti-mouse secondary antibody 
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(1:200, Invitrogen) for detection. Gold antifade reagent mounting (containing Dapi, 
Invitrogen) was performed to stain the nucleus. Staining was examined under 
fluorescent microscope (Olympus IX70, Tokyo, Japan).  
 
2.1.6 Teratoma formation and staining for three germ layers: 
 
Undifferentiated H9 colonies were washed with PBS for three times and subsequently 
detached from mouse feeder layer by treatment of 2mg/ml collagenase IV for 30mins. 
After a brief wash with PBS, two wells of sub-confluent undifferentiated H9 cells 
(approximately 3*10
6
) were immediately injected intramuscularly into thigh muscle 
of SCID mouse to allow teratoma formation. Mouse fibroblast feeder cells were also 
injected in different SCID mouse as negative control. After 7 weeks injection, 
teratomas with diameter of approximately 1.5~2cm were excised from leg of SCID 
mouse and fixed in 4% Para-formaldehyde for 48 hours. The fixed tissues were then 
processed with serial concentration of ethanol and xylene. After fixation, tissues were 
then embedded in paraffin. Following in sectioning to a thickness of 10μm, the 
sections were then stained with basic dye hemotoxylin and eosin (H&E) for staining 




2.2.1 Characterization of undifferentiated H9 hESC 
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hESCs (H9) were cultured on mouse embryonic fibroblast (MEF) cells in the 
presence of bFGF, which was used to maintain pluripotency. H9 hESCs colonies were 
observed every day and passaged every 5-7 days once sub-confulence. Over a long 
term culture, H9 cells were capable of self-renewal and maintained clear margin from 
surrounding MEF cells (Figure 2.1A, E). The expression of essential intracellular 
transcription marker Oct4 for pluripotency and hESC specific surface marker SSEA4 
were confirmed by positive immunocytochemical staining of Oct4 (Figure 2.1C) and 
SSEA4 (Figure 2.1G)[46]. DAPI was used to stain nucleus of all cells including MEF 
feeder cells (Figure 2.1B, F). Phase contrast, DAPI and immunocytochemical staining 
(Oct4, SSEA4) pictures were merged together (Figure 2.1D, H) to differentiate H9 
cell colonies from MEF feeder cells.  
 
2.2.2 EB formation and Teratoma formation 
 
After the H9 cell colonies were removed from feeder cells and cultured in EB 
medium, dissociated H9 colonies formed globular EB aggregates with consistent 
morphology (Figure 2.2). hESCs H9 cells, 3 days and 5 days H9 EBs were subjected 
to polymerase chain reaction and positive expression of transcription factors Oct4 and 
Nanog which are essential for pluripotency were confirmed in all groups (Figure 2.3). 
To further confirm the pluripotency of H9 cells, H9 cells colonies were injected into 
SCID mouse in vivo to form teratomas. First observation of teratoma lumps was 4 
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weeks after injection. Teratomas (7 weeks post injection) were excised from 
euthanized mice and pluripotency to differentiate into all three germ layers were 
further confirmed by histological analysis by H&E staining (Figure 2.4).  
 
A: Phase contrast B: DAPI staining 
  
C: Immunoflurescent staining Oct4 D: Merging 
  
E: Phase contrast F: DAPI staining 
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G: Immunoflurescent staining SSEA H: Merging 
  
Figure 2.1. ES colonies and staining results on pluripotency. Phase contrast picture 
(A, E) and merging after immunocytochemical and DAPI staining (D, H) shows clear 
boundaries between 4 days H9 colonies and mouse feeder layers. DAPI (blue) stains 
the nuclear of all cells. Pluripotent cells with positive Oct4 expression were stained in 
red. Pluripotent cells with positive expression of SSEA were stained in green.  
 
  













Figure 2.3 PCR results for Oct4 and Nanog for 3 different samples with β-actin as 
control. From lane 1 to lane 3 are expression levels of genes for hESCs H9 colonies, 











Figure 2.4 Teratomas were extracted from SCID mouse 7 weeks after implantation. 
Teratomas were cryosectioned and H&E staining was performed for the sectioning 
slides to show cells originated from all three primary germ layers including endoderm, 
mesoderm and ectoderm. Arrows: Granular epithelium and developing gut from 
endoderm. Adipocytes and smooth muscle cells from mesoderm. Neural Rosettes 











 hESCs as a cell model for small molecule 
induced differentiation  
 
 29 
3.1 Introduction:  
 
Despite of the rapid technological improvements in the past decades, we are still 
lacking of enough new drugs for treatment of human disease. And the crisis is 
seemingly getting worse. Down from a high of 53 in 1996 and 39 in 1997, only 29 
drugs were approved by FDA last year[47]. The real problem we face today is not 
because of the lack of chemicals can be used as drugs; it is that we still do not have a 
good platform to examine the function of thousands of chemicals were synthesized 
every day. All synthetic chemists have their own drug library, but out of these huge 
numbers of libraries, only less than 50 drugs were approved every year for use as 
drugs. Screening and later in vitro tests actually resulted in lots of positive hits. 
However, in subsequent pre-clinical and clinical phases, only few drugs can pass 
through. One of the mean reason behind is none of the current In Vitro models is 
good enough to reflect full spectrum of human physiology. Even using primary cell 
lines for testing, there is lack of universal standard in measuring the variations 
between batch to batch. As a potential cell model for drug disvoery, hESCs has been 
used as a source in a few labs, and most of them focus on the process of 
differentiation, using RT-PCR, morphological change and immunocytochmistry to 
identify phenotype of differentiated cell [48]. Such protocols are more theory proof 
rather than setting up the standard of using hESCs as a model. In this study, taking 
hESCs differentiation towards osteogenic lineage as an example, we proposed a set of 
functional assays as a standard of hESCs as a model for drug discovery  
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One of the major areas of stem cell differentiation research is the derivation of 
osteolineage for bone tissue engineering and bone reconstruction. Bone regeneration 
research has become very important gradually because of the increased occurrence of 
bone factures and degenerative diseases in many countries especially those well 
developed ones with a high percentage of elderly population. Particularly, the high 
risk of bone illness such as osteoporosis and osteoarthritis are major public health 
problems for those countries[49]. Minor injuries can be repaired by bone itself 
through remodeling. However, when the source of osteoblasts was compromised at 
the defect site or during osteoporosis when the bone is incapable of self repair, the 
most effective treatment will be regenerative medicine, specifically cell based 
therapies to replenish osteolineage cells in defect site[50].  
 
3.1.1 Osteogenesis from hESCs 
 
Human Embryonic Stem cell differentiation toward osteoblast lineage was first 
reported in 2003[51]. Since then, numerous reports have been published for the 
successful direct generation of osteoblast lineage cells from hESCs. However, most of 
such publications only reported the optimization of culture conditions in In Vitro 
generation such as going through the formation of embryoid bodies or the direct 
plating of hESCs in defined medium with the traditional cocktail 
supplements(ascorbic acid, dexamethason, b-glycerolphosphate or vitamin 
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D3)[52-53]. However, such differentiation usually does not meet our expectations for 
pure osteoblast cultures for transplantation. In this report, we proved that a synthetic 
small molecule named purmorphamine was capable of enhancing the osteogenic 
activities of human embryonic cells.  
 
3.1.2 Why small molecule purmorphamine? 
 
Small molecules serve as useful chemical tools to control stem cell fate and will 
likely to provide new insights into stem cell biology. One approach to generate 
functional small molecules that control stem cells fate involves the use of cell-based 
phenotypic or pathway specific screens of synthetic chemical or natural product 
libraries[54]. In this approach, various naturally occurring and synthetic heterocycles 
known to interact with proteins involved in cell signaling comprise the core 
molecular implants. These included substituted purines, pyrimidines, indoles, 
quinazolines, pyrazines, pyrrolopyrimidines, pyrazolopyrimidines, phthalazines, 
pyridazines and quinoxalines[55]. High-throughput screens of these diverse 
substituted molecules have been done by a group of scientiests in The Script Research 
Institute.  
 
A synthetic molecule, 2, 6, 9-substituted purine named purmorphamine was found to 
direct multi-potent mesenchymal progenitor cells C3H0T1/2 into osteoblast 
lineage[56]. Studies also shown that  purmorphamine is functional in directing 
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differentiation or trans-differentiation other adult stem cells types into osteoblast 
lineage, including Mouse MC3T3-E1 osteoblast progenitor cell, Mouse MC3T3-L1 
Pre-adipocyte lineage, Mouse C2C12  skeletal muscle lineage commited  cells. 
Only one group has shown purmorphamine's capability in differentiating adult stem 
cells from human origin (Human bone Marrow MSC) into osteoblast lineage[57].  
 
In these previous studies, purmorphamine has shown promising results in directing 
adult stem cell differentiation. However, limitations of adult stem cells especially the 
proliferative capacity poses major obstacles in cell replacement therapy for tissue 
repair and regeneration.  Up to date, whether purmorphamine can direct embryonic 
stem cells differentiation into osteoblast lineage is still unknown, either from murine 
or human origin. In this study, we investigated the efficiency of purmorphamine in 
differentiating human embryonic stem cell into osteoblast lineage by comparing with 















Chemical formula: C31H32N6O2 
Solubility: DMSO, cell permeable compound.  
 
3.2 Material and methods: 
 
3.2.1 Cytotoxicity testing of purmorphamine through MTS assay: 
 
As a potential drug for clinical or research use to alleviate bone diseases, 
purmorphamine must be tested for its potential health risks, especially on the viability 
of living cells. MTS assay was used in this study to evaluate the cytotoxicity of 
purmorphamine treatment with three cell lines, human fetal osteoblast cells (hFOB, 
CRL11372, ATCC), human embryonic palatal mesenchyme cells(HEPM, CRL1486, 
ATCC) and fibroblast like cells differentiated from hESCs(H9, ebF).  
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The complete medium used for culturing HEPM and H9 ebF was high glucose 
DMEM supplemented with 10% FBS. Cells were allowed to proliferate in T75 
culturing flasks in above medium until confluence for about 1 week at 37 °C in 
humidified atmosphere with 5%CO2. hFOB cells were cultured in the DMEM F-12 
without phenol red (Invitrogen) supplemented with 10% FBS at 34°C in humidified 
atmosphere with 5%CO2. Confluent cells were then trypsinized and seeded onto 6 
well plates for testing. Three dosage of purmorphamine (5, 10 and 20mM) was tested 
on the cell lines for 4 hours following ISO 10993 standards. DMSO was used as 
control.  
 
MTS assay is a standard laboratory colorimetric assay that measures the activity of 
mitochondrial activity. Enzyme reductase from mitochondria converts yellow MTT 
into purple color formazan. For this experiment, CellTiter96
®
 Aqueous Solution Cell 
Proliferation Assay kit (Promega). MTS reagent is added to the testing wells in the 
concentration of 1:5(MTS reagent: medium vol/vol) and incubated at 37 °C in 
humidified atmosphere with 5%CO2 for 4 hours. The absorbance was read at 490nm 
using Infinite
®
 200 plate reader (Tecan group. Männedorf, Switzerland).  
 
3.2.2 Purmorphamine on H9 hESCs attachment: 
 
The utility of hESCs as a source of master cells to differentiate in to specific cell lines 
are poorly understood. However, it was generally believed that differentiation stimuli 
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should be applied to cells as early as possible during differentiation process to avoid 
spontaneous differentiation of hESCs into ectodermal lineage. Another problem for 
hESCs is that once the cells were detached from MEF layer and split into single cell 
population, the attachment rate to culture dish is very low without MEF supporting. 
Hence, before studying purmorphamine‘s role in osteogensis, whether this drug 
reduces the attachment of hESCs need to be evaluated as well. Approximately 2*10
5
 
cells were seeded onto each well of 24 well plates. Three concentrations (2, 5, 10mM) 
of purmorphamine starting from effective dose cited from literature were added into 
culture medium together with H9 hESCs for differentiation at day 0. After 24 hours of 
treatment, non-attached cells were washed away with PBS for 3 times and MTS assay 
was again performed to evaluate the effect of purmorphamine on cell attachment.  
 
3.2.3 Osteogenesis using H9 hESCs with purmorphamine treatment: 
 
H9 colonies were treated with 1mg/ml collagenase IV for 5mins and cell clumps were 
transferred to 24-well culture plates to create a mono-layer cell culture. For 
differentiation, 4 types of media were used in comparison: 
Base differentiation, DMEM with 10% FBS, 1% DMSO as control 
Purmorphamine induction, DMEM with 10% FBS, 2mM purmorphamine 
Cock-tail induction, DMEM with 10% FBS, 50 μM ascorbic acid, 10 mM 
β-glycerophosphate, and 100nM dexamethasone. 
Purmorphamine and cock tail (CT) induction,  DMEM with 10% FBS, 50 μM 
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ascorbic acid, 10 mM β-glycerophosphate, 100 nM dexamethasone, and 2mM 
purmorphamine 
 
For purmorphamine induction experiments, time point of purmorphamine treatment 
was studied. 2mM purmorphamine was added into culture medium starting from day 
0, 2, 4…14 every other day to find the maximized induction time. Culture medium 
was changed every other day and spend media were collected for protein assays. The 
experiment set up is demonstrated in the figure below. 
 
 
Figure 3.1 Purmorphamine induced osteogenic differentiation with time point study 
in comparison with no treatment. Purmorphamine treatment for cock-tail induction 
groups have the same set up as groups with base differentiation media.  
 
3.2.4 Characterization of osteogenesis: 
 
3.2.4.1 Alizarin red staining: 
 
Groups Day0 Day2 Day4 Day6 Day8 Day10 Day12 Day14
Control base media - - - - - - - -
Control base media + DMSO - - - - - - - -
Treatment 1 + + + + + + + +
Treatment 2 - + + + + + + +
Treatment 3 - - + + + + + +
Treatment 4 - - - + + + + +
Treatment 5 - - - - + + + +
Treatment 5 - - - - - + + +
Treatment 7 - - - - - - + +
Treatment 8 - - - - - - - +
Purmorphamine treatment
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 free) for three 
times and fixed with 4% formaldehyde (sigma) for 20mins at room temperature. The 
plate was then rinsed with distilled de-ionized water for three times and stained with 
500ul of alizarin red working solution in each well for 5 mins at room temperature 
with light protection. The working solutions were then aspirated and the plate was 
rinsed with distilled de-ionized water thoroughly until non-specific staining was 
washed out. The plate was then air dried and pictures were taken under inverse 
microscope.  
 
3.2.4.2 Polymerase chain reaction: 
 
At day 21, differentiated cells were collected. Total mRNA was extracted using 
RNeasy
○R
 Mini Kit (Qiagen, German). Strictly following manufactures instructions, 
total mRNA was extracted and quantified by Nanodrop (Nanodrop technologies, 
Wilmington, DE). cDNA was then generated from 500ng of tRNA using iScript TM 
cDNA synthesis kit(Biorad, Hercules, CA)  following manufacturer‘s instructions.  
 
Conventional PCR was performed using Mycycler, PCR thermal cycler (Biorad). 
Samples were denatured thoroughly at 95°C for 5mins, in each cycle of 35 cycles, the 
samples were then denatured at 95°C for 30 seconds, followed by specific annealing 
temperature for different genes from 55-65°C for 45 seconds, and double strand DNA 
synthesis at 72°C for 1mins and ends up with 72°C for 5mins. β-actin was used as 
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control to normalize PCR reactions. PCR products were further loaded on 2% agarose 
gel electrophoresis with ethidium bromide staining. Bands were visualized using 
Universal Hood (Light Imaging System (Biorad segrate, Milan, Italy)).   
PCR primers are listed below.  
















F: ATG AGA GCC CTC ACA CTC CTC 
61°C 










3.2.4.3 Total cellular protein concentration 
 
Cells from all four groups using different stimulation media were collected at day 21. 
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Cells were rinsed twice with PBS, followed by 15mins lysis using non-denatured 
lysis buffer (20mM Tris HCl pH 8, 137mM NaCl, 1% Triton X-100 and 2mM EDTA) 
on ice with constant agitation. The lysates were then centrifuged at 14000g for 5 mins 
and the supernatants were used for further testing. Total protein was determined in 
cell lysates through a colorimetric assay similar to Lowry assay using DC protein 
assay kit (BioRad). Briefly, the protein samples were first incubated with copper 
tartrate solution in alkaline condition, and subsequently, reduction of a diluted Folin 
reagent was added into each well by copper-treated proteins. The reaction was stable 
from 15mins to 1 hour. Absorbance was read at 750nm using Infinite
®
 200 plate 
reader (Tecan group. Männedorf, Switzerland). Following manufactures instructions, 
total protein concentraion were estimated using a standard curve obtained with serial 
dilutions of BSA (0.15, 0.3, 0.6, 0.9, 1.2mg/ml). 100ul of cell lysate was used for 
quantitation of cellular alkaline phosphatase (AP) and osteocalcin(OC) concentrations 
using AP and OC assay as described below. Cellular level of AP and OC will be 
calculated in relative to total protein concentration.  
 
3.2.4.4 Alkaline phosphatase secretion assay:  
 
Media spent of differentiating hESCs from in vitro differentiation were collected 
every other day and frozen immediately after collection. At day 21, activity of 
secreted alkaline phosphatase in media spent of differentiating cells was measured. 
Briefly, 100ul of alkaline phosphatase yellow liquid substrate for ELISA assay 
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(Sigma catalog no. P7998) was used to monitor the activity. The reaction was taken in 
96 well plates at room temperature for 30mins. 50ul of 3N NaOH solution were then 
added to each well to stop the reaction. The enzyme activity was detected by 
absorbance reading at 405nm. The increment of absorbance readings at 405nm 
directly reflects the AP activity within the samples.   
 
3.2.4.5 Osteocalcin secretion assay: 
 
Similar to AP assay, 100ul of collected media spent was used for OC assay. 100ul of 
samples were added to each well of a 96 well plate coated with osteocalcin specific 
antibodies (Gla-OC EIA Kit, Takara, Japan). The plate was then agitated gently for 
proper mixing for 2 hours at room temperature. After 3 washings with PBS, 100ul of 
antibody-POD conjugate solution was added to each well again for 1 hour with gentle 
agitation at room temperature. Again the plate was washed for 4 times followed by 
adding 100ul of substrate solution into each well and incubated for 15mins at room 
temperature. Lastly, the reaction was stopped by adding 100ul of 1N H2SO4 into each 
well. Absorbance was detected at 450nm and OC concentration was calculated based 
on the standard curve plotted when performing the experiments.  
 
3.2.4.6 Purmorphamine on cell growth and viability test: 
 
H9 hESCs were cultured in DMEM with 10% FBS up to 21 days with or without 
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purmorphamine treatment. MTS assay was performed to study whether 
purmorphamine has any effect on proliferation profile of testing cells. Briefly, MTS 
reagent was added to culture plates at day 7, 14 and 21 and absorbance was taken at 
490nm. Absorbance reading directly reflects the cell number change in culture.  
 
3.2.4.7 Statistical analysis: 
 
Each experiment was performed in triplicates. Statistical analysis was performed 
using SPSS software. Statistical significance was set at 0.05 for one way ANOVA and 
Bonferroni‘s correction for multiple comparisons. Results of the MTS assay, AP assay 





3.3.1 Cytotoxicity testing of purmorphamine: 
 
All chemicals are toxic at very high concentrations, so should the small molecule 
purmorphamine. MTS results from 3 different cells lines suggested that at 3 different 
treatment concentrations from 5 to 20μM, no apparent cytotoxicity was found in 
comparison with control (Figure 3.2). Though there are some variations in the lower 
two dosages (5, 10μM) in treatment of HEPM cells, which the cell viability is less 
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than 100%. Such variability might be resulted from handling procedures as compared 
with the same treatment at 20μM in HEPM and treatment on other two cell lines. 
MTS in cell viability tests suggests that purmorphamine did not generate any 
cytotoxicity up to 20μM treatment. Hence, the proposed concentration of 20μM 
treatment is safe to use.   
 
Figure 3.2 Cytotoxicity of purmorphamine on hFOB, HEPM and H9 ebF. Treatment 
ranging from 5 to 20μM on all cell lines showed cell viability of nearly 100% relative 
to the control group.  
 
3.3.2 Purmorphamine effects on H9 hESCs attachment: 
 
In absence of mouse embryonic fibroblast feeder layers, hESCs single cells suffer 
from very low attachment to culture plates even with gelatin coating. For direct 
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plates directly subject to differentiation stimuli. In the cell attachment assay using 
MTS(Figure 3.3), all 3 dosage of purmorphamine treatment (2, 5 and 10μM) resulted 
in consistently lower attachment rates that are significant from control (DMSO) at 
p=0.05.  
 
Figure 3.3 Purmophamine treatments for cell attachment of H9 hESCs. DMSO was 
used as control. For 2μM treatment, cell attachment was significantly low from 
control group (p=0.041). For 5 and 10μM treatment, cell attachment was significantly 
low from control group (p=0.02 and 0.03 respectively). However, there are no 
significant difference between 2μM treatment and 5, 10μM treatments, though the 
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3.3.3 Purmorphamine induced differentiation of H9 hESCs: 
 
H9 hESCs were trypsinized into single cell suspension prior to seeding for 
differentiation. Same numbers of H9 hESCs single cells were seeded into each well of 
24 well plates subject to two types of differentiation media (basic media and basic 
media with cock-tail supplements) for 21 days. There are two control groups 
(with/without DMSO) in comparison with purmorphamine treatment in each type of 
culture media. For purmorphamine induction groups, the very first treatment of 
purmorphamine was added into culture at different time points starting from day 0 
–14 followed by continuous treatment every other day for treatment periods of 21 –7 
days. Results shown that with purmorphamine treatment, in either basic media or 
supplemented with cock-tail, cell morphology changed from round to spindle shape 
in the early days of differentiation with dense matrix deposition (Figure 3.4). 
Osteogenic lineage commitment was further confirmed by polymerase chain reaction 
analysis. Transcription of active gene (Bone-specific AP, RunxII, Osterix, Osteocalcin) 
from osteogenic lineage were confirmed after differentiation induction (Figure 3.5). 
β-actin was used as internal control. Pluripotent marker Oct4, Nanog was also 
amplified by PCR. Negative transcription of Chondrogenic and adipogenic lineage 
markers COMP and PPARr were confirmed suggesting that purmorphamine only 
stimulates hESCs toward osteogenic lineage.  
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Figure 3.4 Morphological pictures of differentiated cells. Picture on left under 4x 
magnification, dense matrix deposition of differentiated cells was observed after 14 
days. Picture on the right. Cells converted from globular to spindle shape after 14 

































Lane 1. Base medium (BM).  Lane 2. BM+DMSO. Lane 3. BM+PMP D0.  Lane 
4. BM+PMPD2 Lane 5. BM+PMPD4. Lane6. BM+PMPD6. Lane7. BM+PMPD8. 
Lane8. BM+PMPD10. Lane9. BM+PMPD12. Lane10. BM+PMPD14. 
Lane11.Cock-tail (CT) +PMPD8. Lane12. CT+DMSO. Lane 13. CT+PMPD0. 
Lane14. CT +PMPD2. Lane15. CT +PMPD4. Lane16. CT +PMPD6 Lane 17. 
CT+PMPD8. Lan18. CT +PMPD10. Lane19. CT +PMPD12. Lane20. CT 
+PMPD14 
 
Figure3.5. Expression of pluripotency, osteolineage, chondrogenic lineage, and 
adipogenic lineage markers for 20 samples under different inducing media. Each lane 
represents one differentiated sample harvested at 21 days of stimulation. All samples 
showed high level of differentiation towards osteogenic lineage. In groups only 
treated with purmorphamine without cock-tail, osteolineage markers are positively 
expressed suggested that purmorphamine is able to induce hESCs differentiation to 
osteoblast lineage. No positive results were obtained for pluripotent markers Oct4 and 
Nanog suggest that differentiation is thorough enough after 21 days. Smear 
expression of chondrogenic lineage marker COMP and adipogenic lineage marker 
PPARr means that there are minor differentiations towards both lineages.   
 
3.3.4 Production of bone nodules: 
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Alizarin red staining is commonly used to examine the presence of calcium 
deposition by cells of osteogenic lineage. It is an early stage marker of matrix 
deposition which is crucial towards the formation of calcified extracellular matrix 
associated with bone. In this study, alizarin red staining was performed after 21 days 
of induction. Positive alizarin red staining was obtained for all groups. However, 
alizarin condensation in groups with cocktail supplements was generally higher than 
other induction media without cocktail supplements (Figure 3.6A, 3.6B). For 
differentiation under base medium, purporphamine treatment starting from later days 
resulted in relatively more mineralization comparing with control (Figure 3.6A). The 
nodules were very small and only visible under inverse microscope (Figure 3.6C). 
However, for differentiation under cock-tail medium, density mineralization was 
higher when comparing with groups under base medium (Figure 3.6B). Among 
groups under cock-tail medium, starting purporphamine treatment from day 6 to day 
10 (PMP CT6-10) showed the greatest mineralization and obvious nodule formation 
(Figure 3.6D). For other group starting the first purmorphamine treatment from day 0 
to 4 and day 12 to 14, nodule formation were obvious, visible with naked eye but less 
populated than groups of purmorphamine CT4-10.  
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Figure 3.6A Differentiation under base medium. Alizarin red staining was carried out 
in duplicates. There were two control groups, from well 1 to 4. Well 1 and 2 were 
control without any supplements. Well 3 and 4 were control supplemented with 
DMSO. Well 5 to 20 were treated with purmorphamine at different starting point 
ranging from day 0 to day 14. No mineralization was found in the control groups. 















Figure 3.6B Differentiation under cock-tail medium. Alizarin red staining was carried 
out in duplicates. There were two control groups, from well 1 to 4. Well 1 and 2 were 
control with CT supplements (Dexamethason, β-glycerol phosphate, ascorbic acid). 
Well 3 and 4 were CT supplemented with DMSO. Well 5 to 20 were treated with 
purmorphamine at different starting point ranging from day 0 to day 14. 
Mineralization was found in the all groups including control. Mineralization was 
obvious for 5 groups of inducing media: control group without DMSO, and first 
purmorphamine treatment from day 4 to 10. Although other groups also showed 
certain level of positive staining with alizarin red, nodule formation were less 














Figure 3.6C Purmorphamine treatment starting from day 8 in base medium. 
Mineralization was only visible under microscope. Nodules are relatively small under 
4X mangnifcation (Picture on the left). Mineral condensation under 10X 
magnification (Picture on the right)..  
 
 
Figure 3.6D. The CT control group without DMSO (Picture on the left) showed less 
mineralization, comparing with picture on the right which was the purmorphamine 
treatment starting at day 8 of differentiation under inverse microscopy. Pictures were 





3.3.5 Purmorphamine effects on cell growth during differentiation.  
 
Growth curve obtained for H9 hESCs during differentiation shows that growth rate 
was considerably high after 2 weeks of induction, showing age dependent doubling 
(Figure 3.7). In relative to day 7, there are only 1.01 and 1.10 folds of cell number 
increments on average for control and treatment at day 14. The slower growth rate in 
the early days suggested cells were undergoing transition from pluripotent state to 
lineage committed cells. However, at day21, there are 1.35 and 1.73 folds increments 
for control and treatment group relative to day 7, suggesting that purmorphamine 
greatly induces the cell number increment at certain stage of differentiation.  
 
 
Figure 3.7 Cell growth profile during differentiation in DMEM with 10%FBS. With 
the same number (2x10
5
) of cells seeded in each well at day 0, cell numbers were 



























roughly the same at day 7 with a spectral reading of 0.69 and 0.72 for control and 
treatment respectively. At day 14, spectral readings were 0.71 and 0.80 for control 
and treatment respectively. At day 21, spectral readings were 0.94 and 1.26. So after 
21 days purmorphamine induction, there was 34% increase in cell number comparing 
with control group.  
 
3.3.6 Characterization of osteoprogenitors  
 
Osteocalcin is non-collagenous protein secreted by osteoblast cells found in bone and 
dentin. It is generally believed to play important roles in mineralization and calcium 
homeostasis. Synthesized and secreted by osteoblast cells, osteocalcin is used a 
typical marker of osteoblast and osteogenic differentiation. Serum level of osteoblast 
increment is well correlated with bone mineral deposition. Our results show that 
starting purmorphamine treatment from day 6 to day 8 of differentiation increased 
level of osteocalcin in cell extracts (Figure 3.8).  
 
Alkaline phosphatase is present in almost all tissues throughout of the body. However, 
it is particularly concentrated in bone, liver and placenta. We studied both the 
releasing tendency of AP in media spent along the period of differentiation and the AP 
level in cell lysates. Similar to osteocalcin, AP level for the groups starting 
purmorphamine treatment from day 6 to day 8 of differentiation are significantly 
higher than treatment of other time points and control at day 21 (Figure 3.9). AP 
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release into culture media along the differentiation was also studied (Figure 3.10). 
Media spent was collected starting from four days of differentiation. For control 
groups with or without DMSO, there was fluctuation of AP release with one peak at 
day 10 or day 12 followed by a slight decrease. After day 14, AP release increased 
consistently. For groups with purmorphamine treatment, there was no fluctuation in 
AP release. Soon after the treatment of purmorphamine, AP release increased 
consistently for all treatment time points. The highest AP releases were detected from 
CT6, CT8 and CT10 (Figure 3.11).  
 
 
Figure3.8 At day 21, differentiated cell were collected and lysed. Osteocalcin 
concentration was calculated in relative to total protein quantity. Starting 
purmorphamine treatment on day 6 and 8 are much higher than other treatments and 
control. However, no significance level was achieved due to the variation within 





























4, 10, 12 and control.   
 
 
Figure3.9 Alkaline phosphate level in cell lysates at day 21. Level of AP activity in 
cell lysates in groups starting treatment of purmorphamine at day 6 and 8 were 






















Figure3.10 AP secretion tendency in media spent along the time course of 
differentiation. Media spent was collected two days after every purmorphamine 
treatment. For control, media was collected starting from four days of differentiation. 
For control groups with or without DMSO, there was fluctuation of AP release with 
one peak at day 10 or day 12 followed by a slight decrease. After day 14, AP release 
increased consistently. For groups with purmorphamine treatment, there was no 
fluctuation in AP release. Soon after the treatment of purmorphamine, AP release 
increased consistently for all treatment time points. The highest AP releases were 
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Figure3.11 AP activity in media spent at day 20. Groups starting purmorphamine 
treatment at day 6—10 were significantly higher in AP activity from media spent 
comparing with other groups (p<0.05).  
 

































Chapter IV In Vitro biocompatibility 





Titanium implants have been widely used in clinics since 1965. Because of the high 
strength, low weight, outstanding corrosion resistance and low allegenicity, pure 
titanium and titanium alloys have led to a wide and diversified range of applications. 
Such applications, especially in surgery and medicinal fields, require high levels of 
reliable and stable performances that titanium can provide.  
 
Because of those properties titanium possess and lack of substituent, more than 1000 
tones of titanium devices are implanted in patients worldwide every year. There will 
be more and more requests for titanium replacement because of human population 
growth and improvement of living standards until a perfectly substituent was found. 
Until then, Titanium is still one of the most suitable materials that naturally match the 
requirements for implantation in the human body.  
 
Titanium alloys for medical use has been proved to have a significantly higher 
strength to weight ratio than other metal alloys, which enable specialists to design and 
form implants closely tailored to the needs of application. The most essential 
requirement for implants is ‗fit and forget‘, which means once the implants were 
installed, they cannot be replaced readily. The purpose of implantation is to save lives 
or for the long term relief of suffering from pain. Hence, implants must be able to 
hold the promise of compatible to human physiology, mechanical structure of human 
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body and chronic corrosion from body fluids. Corrosion of implants by body fluids 
and tissues may result in high level of metal ions released into our blood stream, 
which will result in severe health concerns.  
 
Another key factor of making titanium and titanium alloys as the most applicable 
material for implantation is osseointegration, which is the capacity for joining with 
bone and other tissues. Once implanted, it can bind with our bone through 
biointegration and our body will not reject it. In dental application, a titanium root is 
introduced into the jaw bone to allow osseointegration over period of time, followed 
by building up the superstructure of the tooth (crown) onto the implant to give 
effective replacement. Because the root is already integrated with the jaw bone, the 
patient is able to use the implant as natural tooth immediately.  
 
We recently managed to develop a porous titanium dental implant. The approach 
adopted to fabricate the titanium dental implant is using 3-dimensional printing (3DP), 
a powder-based solid freeform fabrication method. The main input in a 3DP process 
is 3-dimensional computer drawing. It allows the flexibility of design customization, 
which is beneficial for implant fabrication as tailoring of implant size and shape helps 
to ensure the implant would fit nicely to the patient. A titanium implant of the correct 
alloy will not be corroded once inside our body. To serve as a long term implantable 




To be a biocompatible product, the testing material should be able ―to support 
appropriate cellular activity, without eliciting any undesirable effects in those testing 
cells, or inducing any undesirable local or systemic response in the eventual host‖. 
Biocompatibility tests cover a wide range of topics including safety, effectiveness, 
carcinogenicity, immunogenicity, mutagenicity and even functional tests against the 
host cells. In this chapter, the in in vitro biocompatibility of 3D printing implant was 
tested focusing on cytotoxicity, cell attachement, migration, proliferation and 
osteogensity.  
 
4.2 Material and methods for cytotoxicity testing: 
 
4.2.1 Sterilization of the testing materials: 
 
The implants subjected for testing were first washed with distilled water to flash away 
residual particles during manufacturing of the implant. The implants were then 
autoclaved at 121°C for 20 minutes and drying at 37°C in an oven until use.  
 
4.2.2 Cell culture 
 
L929 cells (CCL-1, ATCC, USA) were cultured in Dulbecco's Modified Eagle 
Medium (DMEM, Sigma, USA) and 10 %( v/v) FBS (fetal bovine serum, HyClone, 
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USA) at 37°C and 5% CO2. Subconfluence culture was treated with 0.25% 
Trypsin-EDTA solution (Sigma, USA) at 37°C for 5 minutes to detach the cells for 
passage or testings.  
 
Agarose gel cylinders with the same dimension as Titanium implants were used as 
negative control for cytotoxicity tests; the same material with encapsulation of phenol 
were used as positive control. The agarose gel cylinders were prepared from 1.5% 
(w/v) agarose which was melted at 120°C for 20 min. When the temperature of 
agarose dropped to 60°C, ultra-pure equilibrated phenol stock solution (5% stock 
solution, USB Corp, USA) were added to liquid-form agarose at the final serial 
concentrations of 0%, 0.0005%, 0.0025%, 0.005%, 0.025%, 0.05%, 0.1% and 0.2% 
respectively. The phenol-agarose solution was carefully poured into a sterile 96-well 
multidish (Nunc, Denmark) and allowed to gel at room temperature for 1 hour. 
Agarose gel cylinders were then harvested from the 96-well multidish by aseptic 
technique.  
 




 in a 6-well plate 
and incubated for 12 hours. The sterilized implants, negative control cylinders and 
positive control cylinders were then carefully placed in the center of L-929 
cell-culture wells in triplicates and further incubated for another period of 48 hours 
with 1ml of fresh media. After removing implants and reference cylinders, cell 
viability was quantitatively analyzed with CellTiter 96 AQueous Non-Radioactive 
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Cell Proliferation Assay (MTS) kit (Promega Corp, USA), strictly following the 
manufacturer‘s instructions. Colorimetric analysis was subsequently performed by 




Figure 4.1 placement of testing materials  
 
Optical density readouts from control groups were used to plot the standard curve of 
phenol-induced cytotoxicity. Curve fitting was performed with a non-linear regression 
model (Sigmoidal dose-response, variable slope). Cytotoxicity of Titanium implant 
was reported by percentage cell viability. The cytotoxic level of implant was also 
converted to equivalent dosage of phenol with the regression model.  
4.2.3 Cell attachment tests using hFOB:  
 
Cell adherence and normal growth on the surface are the prerequisite of osteogenic 
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function of titanium implants. Therefore, we observed cell adherence and growth on 
titanium implant in vitro.  
 
Human fetal osteoblast-like cells (hFOB, CRL-11372, ATCC) were expanded in 1:1 
mixture of Ham's F12 Medium Dulbecco's Modified Eagle's Medium (without phenol 
red, Invitrogen, USA), 0.3mg/ml G418 (Gibco, Invitrogen, USA) and 10 % FBS at 
35°C and 5% CO2. Confluence culture of CRL-11372™ human fetal osteoblast-like 
cells were washed with 1X PBS (phosphate buffered saline) for 3 times followed by 
0.25% Trypsin-EDTA treatment for 5mins to detach cells from cell culture flask. 
Total number of cells collected was calculated after counting the cells using 
Hemacytometer. Cells were suspended in 10% sucrose after a brief centrifugation to 
achieve a concentration of 5*10
5
 cells/25ul. Implants will be separated into 2 groups.  
 
Group 1: to seed the cells with the aid of hydrogel.  
25ul of cell suspension was mixed with equal volume of hydrogel (PuraMatrix™ 
from BD Biosciences) and seeded through the pores of the implants. The implants 
were then carefully placed into 1ml of differentiation medium for gelling. After 
placing the implants, medium were changed every 10mins in the first 30mins to 
adjust the pH to the optimized condition for cell attachment, proliferation and 
differentiation.  
 
Group 2: to seed the cells without the aid of hydrogel 
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       25ul of cell suspension was seeded onto the entire surface (inner and outside) 
the implant directly. The implants were then placed into the differentiation medium.  
 
Twelve hours after seeding, titanium implants were transferred into a new well 
containing differentiation medium. Cells, which had not attached to implants and 
remained in the original wells, were measured with CellTiter 96 AQueous 
Non-Radioactive Cell Proliferation Assay (MTS) kit. Optical density (OD) was read 
at 490nm. The readings of the same number of cells in wells without implants were as 
negative control. The percentage of unattached cells (%) was calculated as 
100×ODexperimental group/ODcontrol. Percentage of attached cells to implant was 
then calculated using the percentage of unattached cell subtracted by 1.  
 
4.2.3.1 FDA staining to examine cells on implants:  
 
At day 14, FDA and PI staining was performed to view the cell attachment directly 
under fluorescent microscope. Briefly, implants were placed in 20ul of FDA/PI (1:1) 
diluted in 980ul of PBS in a total volume of 1ml for 5mins. The implants were then 
washed with PBS for 3 times before viewing. FDA (green) stains the cytoplasm of 
cells and PI (red) stains the nucleus of dead cells.  
4.2.3.2 Collagen I staining to examine the matrix secretion: 
 
At day 14, collagen type I fluorescent staining was performed to the implants. Briefly, 
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the implants were incubated in the rabbit anti-human collagen I primary antibody 
(70X dilutions in PBS with 0.1% BSA as recommended, Chemicon, USA) for 45mins 
at room temperature. After 3 washes with 1X PBS, implants were incubated in Alexa 
Fluor 594-conjugated goat anti-rabbit IgG secondary antibody (100X dilution PBS 
with 0.1%BSA, Molecular Probes, Invitrogen) for 20mins at room temperature. FDA 
was counter stained to the implants after antibody staining. The implants were then 
washed extensively with PBS before fluorescent microscopy.  
  
4.2.3.3 Data analysis 
 
Results of the MTS assay and Osteocalcin secretion assay were expressed as 
mean±standard derivations (calculated from triplicates). 
 
4.3 Results:  
 
4.3.1 Cytotoxicity of titanium implant: 
 
Microscopy analysis revealed that L-929 retained normal spindle-shaped morphology 
and cell density after incubation with titanium implants for 48 hours (Figure 4.2). It is 
reported by quantitative MTS assay that phenol-encapsulated agarose gel cylinders 
exhibited the growth of L-929 in a dose-dependent manner (Figure 4.3). The results 
validated the application of agarose gel cylinders as reference materials to address the 
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cytotoxicity of titanium implants.  
 
After 48-hour direct contact with implants, L-929 cells displayed a high level of 
viability, 99.534%±1.582% (Mean±SD). Cytotoxicity of implants was equivalent to 
0.0000529% phenol-encapsulated agarose gel cylinders as shown in Figure 4.3 
(converted from percentage cell viability with the non-linear regression model at 95% 
confidence interval).  
 
A more direct bar chart comparison of cytotoxicity between implant and reference 
materials was also presented (Figure 4.4). No difference in L-929 cell viability was 
observed between titanium implant and negative control, while cell viability of 
titanium implant group was very significantly higher than that of positive control 
group with 0.1% phenol dosage (P<0.0001). In sum, titanium implant displayed an 




Figure4.2 Cell morphology around the testing materials. Dark area was the testing 
material. There was an obvious difference in the density of cells and there 
morphology. In the testing groups, there were more cells and cells are in spindle 
shape comparing with positive control group where there were less cells and cells are 
rounded up.  
 
 
Figure4.3 Dose response curve on cytotoxicity of phenol on cell viability. Titanium 
 68 
implant shows the highest percentage of viable cell than all dose of positive control.  
 
 
Figure4.4 Cell viability in testing groups are the same as negative control achieving 
almost 100% of cell survival rate which is significant high from the positive control 





Figure4.5. A.Without hydrogel embedding, cells migrated to the culture dish after 12 
hours of seeding. B. cells embedded in hydrogel were entrapped inside the implant 12 





 cells were seeded on/into the implant with and without embedded in 
hydrogel. More than 80% of the cells remain viable 12 hours seeding after the 
implants after trypsinization for groups embedded in hydrogel. For group seeded the 
 hFOB cells presence in implant


































cells directly on the implants, MTS assay is unable to detect and estimate number of 
cells attached to implants after trypsinization.  
 
4.3.2 Cell attachment test of the implant 
 
hFOB cells were seeded on the implant with or without embedded into the 
biodegradable hydrogel. After seeding the cells with the aid of hygrogel and placed 
into culture medium, gelling occurs rapidly and ensures a high percentage of cells 
entrapped in the implants allowing for further attachment (Figure 4.5b). Under 
microscopic observation, most cells in the direct-seeding wells maintain suspending 
morphology and attached to the culture dish twelve hours after seeding (Figure 4.5a). 
Quantitatively, only less than 20% of the total cells seeded were found to have 
migrated from gel-implant system to the culture dish at day1 (Figure 4.6). Hence, 
more than 4*10
5
 cells have successfully been kept in the implant. After replacing the 
implant to a new well, only a limited No. of cells attached to the culture dish were 
observed in the adjacent region of the implant, suggesting that cells were carried over 
by the implants and the gel-implant system are reliable in keeping the cells in the 3-D 
culture. Without the aid of hydrogel, almost all cells migrated from the implant to the 
culture dish at day1 (P<0.001, Figure 4.6).  After being detached by 0.25% 
Trypsin-EDTA and being counted, only 400 cells were estimated to have attached to 
the implant after 12 hours of seeding. It suggests that hydrogel embedding provides a 
more efficient way to keep high concentration of cells within implant at the beginning 
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of differentiation than direct seeding.  
 
4.3.3 Cell migration, proliferation in the implant 
 
After being continuously cultured for 14 days, the surface of titanium implants using 
both cell-seeding methods was fully covered with living cells which were stained by 
FDA (green, Figure 4.7A, B). Among these cells, only a minority of dead cells, which 
were stained by PI, was observed (red, Figure 4.7C, D). It means that once attached, 
cells can proliferate quickly on titanium implants no matter how low the starting cell 
density is. Hence, titanium implants are supportive to cell growth. Additionally, 
although hydrogel-implant system has an advantage in facilitating cell attachment at 





Figure 4.7 Microscopy pictures of FDA and PI staining for cells attached to the 
implants after 14 days of seeding. A. Under 4X magnification, cells were all over the 
surface of the implants. B. magnified view of the cells on implant, cells filled 
between implant surface particles. C. FDA and PI staining for cells seeding without 
hydrogel, implants were fully covered with viable cells (green), only a few dead cells 
(Red) were observed.  D. FDA&PI staining for cells seeding with hydrogel.  
 
4.3.4 Cell function in the implant 
 
At day 14, both titanium implants were fully adhered by viable hFOB cells (green, 
Figure 4.8) all over the surface of implants for both seeding with or without hydrogel. 
With specific fluorescent staining, Collagen type I, a major matrix protein in bone, 
was stained red in many surface areas of implants. Under 4×magnification, matrix 
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formed by secreted collagen I (red) tightly bonded to the implants below viable cells 
to support their attachment. Under 10×magnification, plenty of matrixes deposition 
could be easily observed, particularly around the edges and corners of the implants. It 
suggests that titanium implants not only support the proliferation of hFOB cells, but 




Figure4.8. Collagen I (red) and FDA (green) co-staining for the 3DP implant 2 weeks 
after differentiation. On the left side, hFOB seeding without peptide hydrogel shows 3 
different sides of the 3DP implant: top, side and bottom respectively. FDA (green) 
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staining shows cells were able to attach, proliferate and migrate on the 3DP implant in 
the differentiation medium. Collagen I (red) staining shows normal physiological 
function of hFOB cells. On the right side, hFOB seeding encapsulated in peptide 
hydrogel. All pictures on top 3 rows were taken under 1.25X magnification. 4X 
magnification view shows more cells for hydrogel embedding group before seeding. 
10x magnification view for cells connecting 3DP implant particles with dense 









Chapter V  
Osteogenic differentiation of hESCs as a 
model in 3D implants testing 
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5.1 Inctroduction:  
 
Implants for bone regeneration were used as scaffold for cell attachment, growth, 
differentiation and ultimately integrate with our body skeletal system. Limitation of 
traditional transplantation with self/donor tissue/primary cells is lack of reproducible 
transplant material, resulting in disappointment over high expectations. As a 
promising cell source in regenerative medicine, a standard must be set in the use of 
hESCs as a model for implant testing.  
 
This study aims to evaluate supportive role of this novel 3DP porous titanium implant 
with human embryonic stem cells (hESCs) focusing on two major topics. One is to 
find out whether this 3DP implant has any effects over the proliferation testing cells. 
Another is to find out whether this 3DP implant is able to support differentiation of 
hESCs towards osteogenic lineage.  
 
5.2 Material and methods:  
 
5.2.1 Cell seeding 
 
For osteogenic differentiation in 3D printing implants, H9 hESCs, 3days EBs, 5 days 
EBs and their specific single cells suspensions obtained through trypsinization were 
seeded into the implants using the same hydrogel as previously described, followed 
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by the osteogenic inducement in DMEM containing 5% FBS, 10mM Sodium 
β-Glycerophosphate (Sigma), 50μg/ml Ascorbate-2-phosphate (Sigma), 10-8 M 
Dexamethasone (Sigma) and 1% Penicillin-Streptomycin solution (Invitrogen).  
 
Immediately after cell seeding, titanium implants embedded with cells were incubated 
in osteogenesis-inducing medium for 21 days. Culture media was collected from the 
titanium implants wells every 2 days and stored at -80°C for osteocalcin 
quantification using a Gla-type Osteocalcin EIA kit (Takara Inc., Japan) following the 
manufacturer‘s instruction. Standard curve fitting was performed with a non-linear 
regression model. Concentrations of osteocalcin secretion in sample media were 
calculated based on the standard 
 
5.2.2 Cell growth in the 3D implant 
 
At day 7, 14 and 21 days of differentiation, implants were washed with PBS for 3 
times followed by trypsinization. After 5mins centrifuge at 300g, cell pellets were 
collected and resuspended in base media (DMEM with 10%FBS). Cells collected 
were subjected to MTS assay as previously described. Spectral reading from this 
colorimetric assay was analyzed to compare the cell growth profile in the implants 
among different seeding groups.   
 
5.2.4 AP secretion assay 
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Media spent from differentiating H9 hESCs from 3-D culture were collected every 
other day and frozen immediately after collection. At day 21, activity of secreted 
alkaline phosphatase in media spent of differentiating cells was measured. Briefly, 
100 ul of alkaline phosphatase yellow liquid substrate for ELISA assay (sigma 
catalog no. P7998) was used to monitor the activity. The reaction was taken in 96 
well plates at room temperature for 30mins. 50ul of 3N NaOH solution was added to 
each well to stop the reaction. The enzyme activity was detected by reading 
absorbance at 405nm. The increment of absorbance readings at 405nm directly 
reflects the AP activity within the samples.   
 
5.2.4 Osteocalcin secretion assay:  
 
Media spent were collected every other day in 3-D differentiation culture too assess 
levels of OC (Osteocalcin) secretion. OC secretion was measured using a 
commercially available assay kit from Takara. Inc. briefly, 100ul of media spent was 
added to antibody coated plate for 2 hours at room temperature followed by 3 washes 
with PBS. POD conjugated antibody were then added and incubated at room 
temperature for 1 hour in dark. After 4 washes with PBS, substrate was added and 
incubated for 15mins at room temperature in dark. The reaction was stopped by 
addition of 100ul of 1N H2SO4 and data collected after reading at 450nm. Standard 
curve was plotted using pure osteocalcin provided in the kit. Concentrations of 
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secreted osteocalcin in sample media spent were calculated based on the standard 
curve plotted.  
 
5.2.5 Collagen I staining to examine the matrix secretion: 
 
Collagen I staining was again performed using exactly the same method as described 
in chapter IV.  
  
5.2.6 Data analysis 
 
Results of the MTS assay and Osteocalcin secretion assay were expressed as 




5.3.1 Growth of H9 hESCs and subsequent derivatives in implants: 
 
To test the implants, cells were seeded as H9 hESCs, 3 days EB and 5 days EB and 
their respective single cells. Cell growth profile on implants of different seeding 
groups was studied at day 7, day 14 and day 21. Seeding as single cell suspension 
into the implant showed cell death in the first 7 days post seeding except for seeding 
as 5 days EB single cell suspension. This may primarily because cells from H9 
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hESCs and 3 days EB colonies are more pluripotent than cells from 5 days EB and 
resulted in low survival rate after splitting. Cell number started increasing slowly 
from 7 to 21 days (Figure 6.1). While for groups seeding as cell clumps, unlike those 
groups seeding as single cell suspensions, cell growth rate steadily increased 
immediately after seeding with accelerated growth speed after day 14. At day 21, 
comparing with day 0, cell number were 3.3, 6.5 3.3 folds increased for H9 cell 
clumps seeding, 3 days EB seeding and 5 days EB seeding (Figure 5.1).  
 
5.3.2 Characterization of H9 hESCs on osteogenesis: 
 
After 21 days culture in osteogenic inducing medium supplemented with 
Dexamethason, ascorbic acid and β-glyceral phosphate, Collagen I and FDA 
co-staining were performed for differentiated cells on the implants. For groups of 
cells seeding as cell clumps, there were generally more viable cells (Figure 5.2 Green) 
after 21 days of differentiation than groups seeded as single cell suspension, which 
was also confirmed by previous quantitative studies on cell growth profile. However, 
for groups of cells seeded as single cell suspension, there were more collagen I 
expression (Figure 5.2 Red).  
 
To further investigate the role of implants on osteogenic differentiation of hESCs. AP 
activity in media spent along the time course of differentiation was studied. Groups 
seeding as cell clumps showed higher AP activity than their respective single cells 
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seedings (Figure 5.3). For groups seeding as ES cell clumps, AP secretion increased 
continuously over 20 days of differentiation in 3D environment with the highest 
activity detected up to 1.6. AP secretion fluctuates in a lower range below the group 
of seeding cells as ES cell clumps for all other groups between 1.3 and 1.4. Lowest 
AP activity was detected from 5D EB single cells seeding despite that the total 
number of cells at day 21 is the greatest among all groups.  
 
OC secretion level for hESCs and 3 days EB seeding was also examined along the 
time course of differentiation (Figure 5.4). 3D EB seeding for differentiation was 
generally higher than ES clumps seeding in early days up to day 12 before it started 
to decrease. After day 12, OC secretion from ES seeding group increased and 























































Figure 5.1 Cell growth profile on implant for different seeding groups. Seeding as 
single cell suspension into the implant showed cell death in the first 7 days post 
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 85 
seeding except 5D EB single cell suspension seeding. For seeding as cell clumps, cell 
growth rate steadily increase after seeding. At day 21, comparing with day 0, cell 
number were 3.3, 3.3 and 6.5 folds increased for ES clumps seeding, 3 days EB 

























Figure 5.2 Collagen I and FDA co-staining for differentiated cells on implants after 
21 days of treatment in cocktail differentiation media. A. hESCs cell clump and 
hESCs single cells seeding. B. 3 days EB and 3 days EB single cells seeding. C. 5 
days EB and 5 days EB single cells seeding. There are generally more viable cells 
(Green) in groups seeding as cell clumps and less collagen deposition (Red) than 





























































Figure 5.3 AP activity in media spent along the time course of differentiation. 
Seeding as cell clumps shows higher AP activity than their respective single cells 
seeding. For groups seeding as ES cell clumps, AP secretion increased continuously 
over 20 days of differentiation in 3D environment with the highest activity detected 
up to 1.6. AP secretion fluctuates in a lower range below ES cell clumps seeding for 
all other groups between 1.3 and 1.4. Lowest AP activity was detected from 5D EB 































Figure 5.4 OC secretion level along the time course of differentiation. OC level 
fluctuates along the time course of differentiation for ES cell clumps seeding and 3D 
EB seeding. 3D EB seeding for differentiation was generally higher than ES clumps 
seeding in early days up to day 12 before it started to decrease. After day 12, OC 
secretion from ES seeding group increases and remained higher than 3D EB seeding 































Chapter VI Discussion 
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Despite the great effort of big pharmas and research institutions put in drug discovery, 
the new drugs approved by US. FDA did not keep up with the steadily increased 
expenditures. Over the past 58 year from 1950s, there are 1222 new drugs have been 
approved to for clinical usage. However, only 21 new drugs was approved by FDA 
last year[47]. And only in last year, the number of dollars spend on R&D of new 
drugs was more than 50 billion US dollars[58]. The innovation gap between R&D 
spending and approved new drugs remains high and continues increasing. One of the 
major increase in spending is from the increasing of high cost in conducting clinical 
trials, especially in conducting phase II and phase III trials[59]. Even if the drug 
passes all trials, it may also be withdrawn because of severe side effects. In 1998, 
Posicor, which was used to treat hypertension, was withdrawn by Roche because of 
reducing liver enzymes. In 2001, an anti-cholesterol drug was with drawn by Bayer 
because of muscle deterioration. Current preclinical testings involves the use of 
immortalized cells lines or primary cells lines that unable to resemble human 
physiology fully. Either a drug does not passes the clinical trials or passes the clinical 
trials and was withdrawn from market, is mainly because of the preclinical testings 
did not provide a valid result for further testings. The benefit of human embryonic 
stem cells and their derivatives provide great potential in drug discovery in many 
folds from the primary screening to cytotoxicity studies[60]. The availability of 
hESCs and derivatives provide physiological targets that resemble the in vivo tests 
better than any other cell lines in high throughput screening including target 
validation and structure activity relationship. Upon the successful differentiation of 
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neurons, hepatocytes, cardiomyocytes, osteoblasts as well as other type of somatic 
derivatives from hESCs, such derivatives can offer an in vitro system that includes all 
major cell types in major organs in toxicity testings that is beneficial for further in 
vivo counterparts. Hence, the use of hESCs and derivatives as a model in drug 
discovery will not only increase the reliance of finding the right molecule, but also 
minimize the potential failure because of toxicity in further trials.  
 
In the very first part of this study on purmorphamine‘s role in osteogenesis, we did 
not find purmorphamine elicit any obvious cytotoxicity at 20mM, which is also 
suggested by Ding S. etc[56]. However, when incubated with hESCs immediately 
after hESCs seeding for differentiation, cell attachment was greatly interfered by the 
presence of purmorphamine even at very low level of 2mM. Purmorphamine has been 
found to be an active hedgehog pathway agonist targeting smoothened protein 
[61-62]. The mechanism of blocking cell attachement to gelatin coating is still 
unknown.  
 
Bone regeneration involves synthesis of organic matrix secreted by osteoblasts and 
mineral deposition. Studies have shown that Purmorphamine is able to induce direct 
differentiation or trans-differentiation of adult stem cells into osteoblast lineage, 
including Mouse MC3T3-E1 osteoblast progenitor cell, Mouse MC3T3-L1 
Pre-adipocyte lineage, Mouse C2C12 skeletal muscle lineage commited cells and 
human bone Marrow MSC into osteoblast lineage [57, 63-64]. Our results further 
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confirms that purmorphamine is also to induce direct differentiation of hESCs toward 
osteoblast lineage, dense matrix deposition was observed clearly providing necessary 
structures for mineral deposition. 
 
ES cell differentiation into osteoblasts can be defined into three phases, namely the 
proliferation phase, the matrix deposition phase and the mineralization phase[65]. In 
our studies, cell number increased after day 7. The greatest difference between treated 
and untreated cell population starts from day 14 onwards, suggesting that 
purmorphamine may have a role in cell proliferation to certain stage of cells.  
 
It was confirmed that dexamethasone stimulate osteogenic differentiation for 
progenitor cells. AA is required for collagen assembly and β-glyceralphosphate is 
required for mineralization of the collagen[66]. Without all these three supplements, 
treatment with only purmorphamine resulted in positive expression of osteoblast 
markers, RunxII, osterix, bone-specific AP and osteocalcin suggesting that 
purmorphamine is able to direct differentiation towards osteogenic lineage. 
Co-treatment of purmorphamine and cock-tail supplements together resulted in higher 
level of AP level in media spent and larger area of mineralization suggested that 
purmorphamine are synergistic with cocktail supplements in inducing hESCs 
differentiation to osteoblasts.  
 
Among all timepoints of purmorphamine treatment, treatment starts from day 6 to day 
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8 showed the highest AP activity and OC level in both cell lysate and media spent as 
well as largesst area of mineralization comparing with treatment starting from day 0, 
2, 4, 10 and 12. Also, among all treatment groups, AP activities in media are higher 
than control in general. However, there is a difference in the tendency of AP release 
between control groups; this could be explained by the presence of DMSO [67]. In 
line with previous data of characterizing osteogenesis from hESCs, purmorphamine 
could be acting in both directing the differentiation of hESCs towards osteoblast 
lineage and increasing the proliferation rate of osteoprogenitor cells. By starting 
treatment at a specific time point of day 6 to day 8, we can maximize the level of 
osteogenesis to a significant level.  
 
Osteogenisis in 2D was less efficient than in 3D environment as reported [52]. hESCs 
3-dimensional differentiation has been studied many time with different materials and 
shapes of implants. However, all the tests before was focusing on the differentiation 
potential of hESCs in a mature 3D environment. In this study, we looked at a different 
perspective of testing the 3D printing implant using hESCs as a cell model in 
comparison with ATCC human fetal osteoblast cell line. 3D printing titanium 
implants elicit no cytotoxicity as proved by MTS assay. For seeding cells into the 
implants, we used a biodegradable hydrogel to embed the cells to give cells sufficient 
time to migrate and attach to the implants. Without treatment, the scarcity of 
attachment may be resulted by two reasons: firstly, the surface of the implant is not 
suitable for 3-D cells seeding because of the limited surface area facing upward; and 
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secondly, by gravity. When the cells did not attach to the implants tightly, gravity 
pulled the cells down to the culture dish. Although without gel embedding, hFOB 
cells are all over the scaffold after 14 days of seeding. However, such case does not 
apply to hESCs because of the difficulty in hESCs attachment.   
 
Comparing with hFOB cells on testing the scaffold, hESCs and derivatives are 
capable of testing the compatibility of 3D titanium implants on cell attachment, 
proliferation, and differentiation towards osteoblast lineage. hESCs, 3 days EBs and 5 
days EBs and their respective single cells are seeded in the implants. Single cell 
seeding did not proliferate well in line with seeding as cell clumps is mainly because 
ES cells survive better as cell colonies. There were more cells at day 21 for initial 
seeding as 5 days EBs, but AP activity was the lowest comparing with 3 days EBs and 
Hescs. This can be explained by 5 days EBs were believed to be further differentiated 
than hESC cell clumps and 3 days EBs, uncontrolled spontaneous differentiation of 
culturing 5 days EBs resulted in a mixture of cells, which ultimately limited the 
number of cells can be differentiated to osteoblast cells. However, for hESCs and 3 
days EBs, majority of the cells are still pluripotent giving much chances of osteogenic 
lineage commitment when treated with osteogenic medium.  
 
Among all groups, seeding as hESC clumps shows the highest AP activity up to 1.6 
comparing with all other groups fluctuating among 1.2 to 1.4. AP secretion tendency 
starts increasing from day 0 up to day 16 where it reaches the peak. In literature, 
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levenberg and his colleagues compared osteogenic differentiation of hESCs between 
fibronectin-coated dishes and scaffolds and X.F Tian and his colleagues compared 2D 
culture and fibrin glue coated 3 D cultures [28, 52]. Both showed that 3D system 
showed higher expression level of osteogenic differentiation associated proteins. 
However, their perspective of study is focusing on comparison of 2D and 3D systems; 
neither has optimized the conditions for comparing in seeding different stages of 
hESCs (cell clumps, single cells and EBs). In our study of the 3D system, we first 
optimized the condition for seeding using hydrogel. And then characterized the 
osteogenic potential of different stages of pluripotent stem cells and confirmed that 
seeding as hESCs cell clumps is the best seeding method for lineage directed 
differentiation.  
 
The perspective of this study is focused on the potential of hESCs and their directed 
differentiation as a potential cell model in drug discovery and implant testing. In the 
first part of the study, we not only proved that hESCs can be used as testing the new 
chemicals as stimuli in driving differentiation towards osteogenesis, but also 
optimized the time of treatment that optimize the differentiation. We proved that what 
current immortalized somatic cell lines or primary cells lines can do in new drug 
testing, hESCs are capable of doing so. In the second part of our studies to test 3D 
printed implants, comparing with hFOB cells, hESCs can perform as good as the 
immortalized cell line in generating osteoblast specific protein markers and form 
matrix. Differentiated hESCs are able to attach and proliferate in the implant 3D 
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system. With both the potential in new drug testing and implant testing, hESCs are far 
better cell model than immortalized cell lines in resembling normal human cell 
physiology and primary adult stem cells lines in the homogeneity of long term 
culture.  
 
Although there are problems of using hESCs as cell model such as the maintenance 
of pluripotency to ensure homogeneity of cells before differentiation, the difficulty in 
maintaining long term culture in feeder free condition and the low survival rate of 
hESCs after trypsinzed into single cells suspension, these problems will likely be 
solved in the near future. The derivation of differentiated human models is not only 
restricted to osteoblast lineage, it can also be used as a model in other lineages such 
as hepatocytes, cardiomyocytes and neurons also. Making hESCs as a model will 
certainly provide new insights in improving current model for pre-clinical testings on 
lead screening, drug efficacy and pharmacological processing for drug discovery, it 
will also benefit on the testings of cell-implant interaction, and ultimately leading 
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